Naltrexone

Naltrexone is a competitive antagonist at opioid receptors, with the greatest affinity for the mu-opioid receptor ^[4]. It was approved in the United States for opioid dependence in the 1980s and for alcohol dependence in the 1990s, and is available both as a daily oral tablet and as a long-acting intramuscular injection ^[4]. In alcohol use disorder it is an adjunct to counseling; a Cochrane meta-analysis of 50 randomized trials found that naltrexone modestly but significantly reduced the risk of heavy drinking and the number of drinking days, establishing it as an effective and generally safe option ^[1]. In opioid dependence, the extended-release injectable form supports abstinence after detoxification, with long-term studies reporting sustained opioid-free urine tests and no new safety concerns ^[2].

A distinct off-label practice uses naltrexone at a small fraction of the standard dose, commonly called low-dose naltrexone. Interest here centers on pain and immune modulation rather than addiction. In a single-blind crossover pilot study, low-dose naltrexone reduced fibromyalgia symptoms and improved pain thresholds, with benefit greatest in patients showing markers of inflammation and side effects limited to occasional insomnia and vivid dreams ^[3]. Similar low-dose use has been explored in multiple sclerosis, Crohn's disease, and other chronic conditions, but trials are generally small and the approach is not formally approved.

Naltrexone is a prescription medicine, not a controlled substance, and is widely available as a generic. Standard formulations include oral tablets and a monthly depot injection marketed for both alcohol and opioid dependence ^[4]. Because it occupies opioid receptors, patients must be free of opioids before starting to avoid precipitated withdrawal, and it can blunt the effect of opioid pain medicines. Low-dose preparations are typically compounded, since commercial tablets are made for the higher approved doses.

Naltrexone blocks opioid receptors, so giving it to someone physically dependent on opioids can precipitate acute, severe withdrawal; users must be opioid-free (typically 7 to 10 days) before starting. It can cause nausea, headache, dizziness, and insomnia, and higher doses have been associated with dose-related liver enzyme elevations, so hepatic caution is advised. Because it blocks opioid pain relief, it complicates emergency analgesia and is dangerous if someone attempts to override the blockade with large opioid doses.

Naltrexone is a competitive mu-opioid receptor antagonist that produces a significant pharmacodynamic interaction with opioid analgesics or other opioid agonists. When naltrexone is given to a patient taking opioids, it precipitates acute opioid withdrawal syndrome by blocking the agonist effects; this is well-documented in patients treated for alcohol or opioid use disorder who inadvertently or deliberately take opioids while on naltrexone ^[24]. The onset is rapid and the effects can be severe, including autonomic hyperactivity, pain, and psychiatric symptoms.

Naltrexone's interactions are almost entirely pharmacodynamic and limited to opioid agonists and partial agonists. Alcohol is commonly prescribed with naltrexone in treatment settings, but specific pharmacokinetic interactions have not been clearly documented. Most other medication classes and supplements lack published interaction data with naltrexone.

Checking a whole stack? Run it through interactions + stacks.

Naltrexone was first synthesized in 1965 by chemists at Endo Laboratories in the United States, developed as a long-acting orally effective opioid antagonist during an era of intense interest in treatments for opioid dependence. It received United States Food and Drug Administration approval in 1984 for the management of opioid addiction, marketed as Trexan, and its indication was expanded in the mid-1990s to include alcohol use disorder under the brand name ReVia, following evidence that blocking opioid receptors reduces alcohol craving and reward.

A monthly extended-release injectable formulation, Vivitrol, later broadened its use by improving adherence. In parallel, a very different tradition developed around markedly lower doses; the physician Bernard Bihari and others in the 1980s began exploring so-called low-dose naltrexone, or LDN, for immune and inflammatory conditions, giving rise to an active off-label following. Today naltrexone appears on the World Health Organization's List of Essential Medicines and occupies the unusual position of being both a standard addiction medicine and, at a fraction of that dose, a widely discussed off-label anti-inflammatory.

Naltrexone is well respected on two quite separate fronts. In addiction medicine it is a trusted, non-addictive cornerstone treatment; by blocking the euphoria of opioids and dampening the reinforcing pull of alcohol, it helps people sustain recovery, and its monthly injectable form removes the daily-pill burden that can undermine treatment. Its low-dose incarnation has meanwhile attracted a passionate and growing interest for chronic pain, fibromyalgia, and inflammatory and autoimmune conditions, where the proposed anti-inflammatory action on glial cells offers an appealing, low-side-effect option that patients often describe warmly.

The balanced view is that the addiction indications rest on robust, long-established evidence, whereas the low-dose uses, though genuinely promising and supported by encouraging early studies, remain preliminary and are still being investigated in larger trials. That combination of a proven core role and a hopeful frontier of new applications makes naltrexone one of the more quietly fascinating drugs in modern use.